Insider Transactions in Q4 2022 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 31
2022
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
350
-9.33%
|
$4,200
$12.88 P/Share
|
|
Oct 31
2022
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,165
-5.21%
|
$13,980
$12.88 P/Share
|
|
Oct 31
2022
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
699
-10.15%
|
$8,388
$12.88 P/Share
|
|
Oct 31
2022
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
739
-0.98%
|
$8,868
$12.88 P/Share
|
|
Oct 30
2022
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+20.41%
|
-
|
|
Oct 30
2022
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,207
+12.53%
|
-
|
|
Oct 30
2022
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+21.84%
|
-
|
|
Oct 30
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.68%
|
-
|